Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.

Zhuang H, Wang J, Zhao L, Yuan Z, Wang P.

Int J Cancer. 2013 Nov 15;133(10):2277-83. doi: 10.1002/ijc.28290. Epub 2013 Jun 21. Review.

2.

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.

Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):322-9. doi: 10.1016/j.ijrobp.2014.02.022. Epub 2014 Mar 25.

3.

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.

Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC.

Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468.

4.

High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.

Hata A, Kaji R, Fujita S, Katakami N.

J Thorac Oncol. 2011 Mar;6(3):653-4. doi: 10.1097/JTO.0b013e3181d899bb. No abstract available.

5.

Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.

de Lima Ara├║jo LH, da Silveira JS, Baldotto CS, Zukin M, Ferreira CG.

J Thorac Oncol. 2012 Jun;7(6):1059-60. doi: 10.1097/JTO.0b013e31824cc34a. No abstract available.

6.
7.

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.

Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P.

Drug Des Devel Ther. 2013 Oct 8;7:1179-86. doi: 10.2147/DDDT.S53011. eCollection 2013.

8.

Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.

Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y.

Lung Cancer. 2010 Nov;70(2):174-9. doi: 10.1016/j.lungcan.2010.01.018. Epub 2010 Mar 6.

PMID:
20207442
9.

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.

Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T.

J Thorac Oncol. 2009 Nov;4(11):1415-9. doi: 10.1097/JTO.0b013e3181b62572.

10.

[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].

Shiroma T, Yamaguchi M, Nagai A.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1729-31. Japanese.

PMID:
19838036
11.

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.

Zheng MH, Sun HT, Xu JG, Yang G, Huo LM, Zhang P, Tian JH, Yang KH.

Biomed Res Int. 2016;2016:5807346. doi: 10.1155/2016/5807346. Epub 2016 Feb 24. Review.

12.

Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.

Fang L, Sun X, Song Y, Zhang Y, Li F, Xu Y, Ma S, Lin N.

Cancer Chemother Pharmacol. 2015 Oct;76(4):873-7. doi: 10.1007/s00280-015-2847-z. Epub 2015 Aug 27.

PMID:
26310285
13.

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.

Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS.

Lung Cancer. 2009 Sep;65(3):351-4. doi: 10.1016/j.lungcan.2008.12.011. Epub 2009 Jan 20.

PMID:
19157632
14.

Recovery from carcinomatous meningitis by erlotinib.

Ohara G, Kagohashi K, Kurishima K, Kawaguchi M, Nakayama H, Satoh H.

Onkologie. 2011;34(7):394-5. doi: 10.1159/000329620. Epub 2011 Jun 17. No abstract available.

15.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.

Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y, Ma S.

World J Surg Oncol. 2012 Nov 7;10:235. doi: 10.1186/1477-7819-10-235.

16.

[Brain metastases in pulmonary adenocarcinoma with EGFR mutation: how important is therapy with erlotinib compared to radiotherapy?].

Seidel C, Kortmann RD.

Strahlenther Onkol. 2015 Feb;191(2):205-7. German. No abstract available.

PMID:
25793246
17.

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?

Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A.

Anticancer Res. 2015 Nov;35(11):5797-806. Review.

PMID:
26504000
18.

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.

Zhang J, Yu J, Sun X, Meng X.

Cancer Lett. 2014 Aug 28;351(1):6-12. doi: 10.1016/j.canlet.2014.04.019. Epub 2014 May 23. Review.

PMID:
24861428
19.

Erlotinib induced skin rash spares skin in previous radiotherapy field.

Mitra SS, Simcock R.

J Clin Oncol. 2006 Jun 1;24(16):e28-9. No abstract available.

PMID:
16735697
20.

Supplemental Content

Support Center